Alector, Inc. Common Stock ALEC
HEALTHCARE · BIOTECHNOLOGYi
Market dataready · fetched 2026-11-11T13:57:12.909Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-11T13:48:05.784464293Z
FundamentalsAlpha Vantage · ready · quarter 2026-09-30 · fetched 2026-11-11T13:57:12.492078+00:00
Alector, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | ||||||
| 25Δ | ||||||
| 30Δ | ||||||
| 35Δ | ||||||
| 40Δ | ||||||
| 45Δ | 2.73 | 255.2% | 15.0% | |||
| 50Δ | 2.98 | 258.1% | 13.5% | |||
| 55Δ | 3.23 | 261.1% | 12.0% | |||
| 60Δ | 2.42 | 127.4% | 6.0% | 3.49 | 264.1% | 10.5% |
| 65Δ | 2.27 | 153.9% | 5.4% | 3.74 | 267.0% | 9.0% |
| 70Δ | 2.13 | 180.4% | 4.8% | 3.99 | 270.0% | 7.5% |
| 75Δ | 1.98 | 206.9% | 4.3% | 4.24 | 273.0% | 6.0% |
| 80Δ | 1.83 | 233.4% | 3.7% | 4.50 | 275.9% | 4.5% |
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
30Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
35Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
40Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
45Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 2.73
- IV
- 255.2%
- B/E move
- 15.0%
50Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 2.98
- IV
- 258.1%
- B/E move
- 13.5%
55Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 3.23
- IV
- 261.1%
- B/E move
- 12.0%
60Δ
- Pseudo strike
- 2.42
- IV
- 127.4%
- B/E move
- 6.0%
- Pseudo strike
- 3.49
- IV
- 264.1%
- B/E move
- 10.5%
65Δ
- Pseudo strike
- 2.27
- IV
- 153.9%
- B/E move
- 5.4%
- Pseudo strike
- 3.74
- IV
- 267.0%
- B/E move
- 9.0%
70Δ
- Pseudo strike
- 2.13
- IV
- 180.4%
- B/E move
- 4.8%
- Pseudo strike
- 3.99
- IV
- 270.0%
- B/E move
- 7.5%
75Δ
- Pseudo strike
- 1.98
- IV
- 206.9%
- B/E move
- 4.3%
- Pseudo strike
- 4.24
- IV
- 273.0%
- B/E move
- 6.0%
80Δ
- Pseudo strike
- 1.83
- IV
- 233.4%
- B/E move
- 3.7%
- Pseudo strike
- 4.50
- IV
- 275.9%
- B/E move
- 4.5%
Options history
Table
| Date | IV (%) |
|---|---|
| 120.58% | |
| 142.97% | |
| 140.70% | |
| 122.27% | |
| 177.70% | |
| 158.86% | |
| 125.69% | |
| 123.17% | |
| 134.95% | |
| 106.69% | |
| 97.58% |
Biotechnology
ALLO
Allogene Therapeutics, Inc., a clinical-stage immuno-oncology company, develops and markets genetically engineered allogeneic T-cell therapies for the treatment of cancer. The…
More →ALMS
Alumis Inc. (ALMS) is a prominent player in the aluminum sector, specializing in the development and commercialization of high-performance aluminum solutions for automotive,…
More →ALNY
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered…
More →ALT
Description unavailable
More →ALXO
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. The company is headquartered in Burlingame,…
More →ANAB
Description unavailable
More →